VANCOUVER, Jan. 26 /PRNewswire-FirstCall/ -- AnorMED Inc. (TSX:AOM, AMEX:AOM) advises that it has now received a requisition to convene a special meeting of shareholders for the purposes of replacing the existing Board of Directors from various entities controlled by Felix J. Baker and Julian C. Baker. Felix Baker is a Director of AnorMED Inc. This requisition was received subsequent to the Company's News Release of January 17, 2006. The requisitionists have also provided the Company with a proposed slate of directors consisting of the following individuals who we understand hold the positions below: Felix J. Baker, Managing Partner, Baker Brothers Advisors LLC Joe Dougherty, Partner and Co-Founder, Seaview Securities LLC Henry J. Fuchs, Executive Vice President and Chief Medical Officer, Onyx Pharmaceuticals Incorporated Kenneth Galbraith, President, Gigha Consulting Limited Jacques Lapointe, Executive Chairman of Board, ConjuChem Incorporated Berl Nadler, Partner, Davies, Ward, Phillips and Vineberg, which is counsel to Baker Brothers Advisors LLC Kelvin Neu, Associate, Baker Brothers Advisors LLC The Board's position on the requisition and proposed slate will follow in due course. AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has a product in Phase III development, a product in Phase II development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases including HIV. Additional information on AnorMED Inc. is available on the Company's website http://www.anormed.com/. Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update any forward-looking statements as conditions change. Investors are referred to the discussion of the risk factors associated with the Company's business contained in the Company's Final Short Form Prospectus dated December 1, 2005 and filed with Canadian securities regulatory authorities and available on SEDAR. For further information: Dr. Michael Abrams Elisabeth Whiting, M.Sc. President & CEO VP Corporate Development Tel: 604-530-1057 & Communications E-mail: Tel: 604-532-4667 Cell: 604-763-4682 E-mail: DATASOURCE: AnorMED Inc. CONTACT: Dr. Michael Abrams, President & CEO, Tel: (604) 530-1057, E-mail: ; Elisabeth Whiting, M.Sc., VP Corporate Development & Communications, Tel: (604) 532-4667, Cell: (604) 763-4682, E-mail:

Copyright